
    
      This is a prospective, non-randomized, observational, single arm, cohort study, wherein 200
      patients of unresectable LA SCCHN will be enrolled. The eligibility of the patients will be
      decided by the Investigators based on the locally approved label. The patients will be
      treated with Cetuximab in combination with RT for a duration of 8 weeks and then followed up
      for 3 years. The objectives of this study are to record safety and efficacy information on
      the treatment combination in the general population.
    
  